Montelukast Ratiopharm (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Ratiopharm, is a leukotriene receptor antagonist presented as a tablet for buccal, cutaneous, dental, nasal use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast Ratiopharm is indicated for conditions involving leukotriene‑mediated inflammation.

- Asthma (maintenance therapy): reduces frequency of bronchospasm and improves overall control. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate pain in the head. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: occasional dry or productive cough.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Neuropsychiatric events: agitation, depression, or suicidal thoughts. - Hepatic dysfunction: elevated liver enzymes or hepatitis.

Before prescribing Montelukast, clinicians should consider several safety aspects.

- Assess asthma control: ensure patient’s asthma is stable before initiating therapy. - Monitor for neuropsychiatric symptoms: watch for mood changes or suicidal ideation. - Evaluate liver function: consider baseline tests in patients with hepatic disease. - Use caution in children: adjust monitoring based on age and response. - Review concomitant medications: check for potential interactions affecting leukotriene pathways. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture.

Montelukast can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Phenobarbital: may reduce montelukast plasma concentrations. - Rifampin: induces metabolism leading to decreased efficacy.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine): may increase risk of neuropsychiatric effects. - Beta‑agonists: additive bronchodilation may require dose adjustment. - Warfarin: occasional reports of altered INR, monitor coagulation.